Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.

摘要: Background C225 is an antibody to the epidermal growth factor receptor (EGFR), and inhibits of various tumour cells. The currently being used as a therapeutic agent in several clinical trials patients with carcinomas. Objectives To determine investigate cutaneous side-effects cancer treated C225. Methods We clinically examined 10 C225, performed immunohistochemical situ hybridization studies on skin biopsies. Results most common reaction therapy was development acneiform follicular eruption, which pronounced face, chest upper back typically manifested week after onset treatment. consistency morphology timing findings different following monotherapy strongly suggested direct biological effect antibody. Additional dermatological included focal areas tender paronychial inflammation toes fingers small aphthous ulcers oral mucosa. Serial punch biopsies before treatment (at 8 days) revealed two main patterns: superficial dermal inflammatory cell infiltrate surrounding hyperkeratotic ectatic infundibula, suppurative folliculitis. In intraepidermal acantholysis found, Microbiological cultures failed reveal infectious aetiology. Immunohistochemical subset showed increase expression p27 Kip1 keratinocytes Conclusions Our support concept that plays part vivo regulation homeostasis by EGFR.